# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ThinkEquity analyst Ashok Kumar initiates coverage on BioVie (NASDAQ:BIVI) with a Buy rating and announces Price Target of $3.
SUNRISE-PD to evaluate the effect of bezisterim (NE3107) on motor and non-motor symptoms in ~60 patients with Parkinson's d...
Full Dataset from Phase 2a trial in Parkinson's Disease suggest patients treated with bezisterim experienced significant im...
"Bezisterim" has been approved as the non-proprietary name for NE3107 Data shows how bezisterim may be restoring homeos...
BioVie Inc. (NASDAQ:BIVI), ("BioVie" or the "Company"), a clinical-stage company developing innovative drug the...